CLINICAL_TRIALS
trial_result
· 2020-03-27
Clinical Trial Update: Duration of hSBA Response After a Primary Series of Bivalent rLP2086 Followed by a Booster Dose [Phase 3]
Summary
Phase 3 trial update assessing duration of hSBA response after a primary series of bivalent rLP2086 with a booster dose.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Pfizer | Conditions: Meningococcal Infection | Phase 3 | Status: COMPLETED | Results posted: 2020-03-27